8-K

Aileron Therapeutics, Inc.

Date: February 23, 2023

/s/ Manuel C. Alves-Aivado

Manuel C. Alves-Aivado, M.D., Ph.D.

President and Chief Executive Officer

0001193125-23-046516.txt : 20230223 0001193125-23-046516.hdr.sgml : 20230223 20230223160601 ACCESSION NUMBER: 0001193125-23-046516 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230216 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Other Events FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC CENTRAL INDEX KEY: 0001420565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38130 FILM NUMBER: 23659600 BUSINESS ADDRESS: STREET 1: 285 SUMMER STREET STREET 2: UNIT 101 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-995-0900 MAIL ADDRESS: STREET 1: 285 SUMMER STREET STREET 2: UNIT 101 CITY: BOSTON STATE: MA ZIP: 02210 8-K 1 d433980d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 16, 2023

Aileron Therapeutics, Inc.

(Exact Name of Company as Specified in Charter)

Delaware

001-38130

13-4196017

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

285 Summer Street, Unit 101

Boston, MA

02210

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 995-0900

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol

Name of each exchange

on which registered

Common Stock, $0.001 par value per share

ALRN

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.05

Costs Associated with Exit or Disposal Activities

On February 16, 2023, the Board of Directors (the “Board”) of Aileron Therapeutics, Inc (the “Company”) determined to reduce the Company’s remaining workforce from nine to three employees. The determination to effect the workforce reduction was made in connection with the Company’s decision, further described below, to terminate its Phase 1b breast cancer trial of ALRN-6924 and further development of ALRN-6924. The workforce reduction is designed to reduce the Company’s operating expenses while the Company explores a range of strategic alternatives. The workforce reduction is expected to be completed by the end of the first quarter of 2023.

Affected employees will be offered separation benefits, including severance payments along with temporary healthcare coverage assistance. The Company estimates that the severance and termination-related costs will be approximately $1.0 to $1.1 million and expects to record these costs in the first quarter of 2023. The Company expects that payment of these costs will be made through the second quarter of 2023. The Company’s estimate of costs and the expected timing for recording and paying those costs are subject to a number of assumptions and actual results may differ. The Company may also incur other costs not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction.

Item 8.01

Other Events

On February 21, 2023, the Company issued a press release announcing that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia. The primary endpoint of the Phase 1b open-label trial, which was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide, or “TAC” chemotherapy, was duration and incidence of severe neutropenia in cycle 1. Incidence of chemotherapy-induced alopecia (hair loss) was a secondary endpoint. Based on these findings, the Company has decided to terminate the Phase 1b breast cancer trial and further development of ALRN-6924.

The Company also announced that it is exploring a range of strategic alternatives to maximize stockholder value. The Company has engaged Ladenburg Thalmann & Co., Inc. to act as a strategic advisor for this process. Strategic alternatives that are being evaluated may include, but are not limited to, an acquisition, a merger, a business combination, a sale of assets or other transaction. There is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms. The Company does not intend to comment further on this process unless or until the Board has approved a definitive course of action or it is determined that other disclosure is appropriate.

Forward-Looking Statements

Statements in this Current Report on Form 8-K about the Company’s future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company’s workforce reduction and the costs expected to be incurred in connection with the workforce reduction and the outcome of the Company’s exploration of strategic alternatives. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ

materially from those indicated by such forward-looking statements as a result of various important factors, including whether the workforce reduction will results in the costs and the savings anticipated; whether the Company will identify a strategic transaction to pursue and whether such a transaction may be consummated on favorable terms, on a timely basis or at all; and the other risks factors discussed in the “Risk Factors” section of the Company’s annual report on Form 10-K for the year ended December 31, 2021, filed on March 28, 2022, and quarterly report on Form 10-Q for the quarter ended September 30, 2022, filed on November 1, 2022, and risks described in other filings that the Company may make with the Securities and Exchange Commission. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-101.SCH 2 alrn-20230216.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 alrn-20230216_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 alrn-20230216_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Feb. 16, 2023
Cover [Abstract]
Entity Registrant Name	AILERON THERAPEUTICS INC
Security Exchange Name	NASDAQ
Amendment Flag	false
Entity Central Index Key	0001420565
Document Type	8-K
Document Period End Date	Feb. 16, 2023
Entity Incorporation State Country Code	DE
Entity File Number	001-38130
Entity Tax Identification Number	13-4196017
Entity Address, Address Line One	285 Summer Street
Entity Address, Address Line Two	Unit 101
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
City Area Code	(617)
Local Phone Number	995-0900
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, $0.001 par value per share
Trading Symbol	ALRN
Entity Emerging Growth Company	false

XML 6 d433980d8k_htm.xml IDEA: XBRL DOCUMENT 0001420565 2023-02-16 2023-02-16 AILERON THERAPEUTICS INC NASDAQ false 0001420565 8-K 2023-02-16 DE 001-38130 13-4196017 285 Summer Street Unit 101 Boston MA 02210 (617) 995-0900 false false false false Common Stock, $0.001 par value per share ALRN false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, dei:SecurityExchangeName - d433980d8k.htm 7 d433980d8k.htm alrn-20230216.xsd alrn-20230216_lab.xml alrn-20230216_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d433980d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d433980d8k.htm" ] }, "labelLink": { "local": [ "alrn-20230216_lab.xml" ] }, "presentationLink": { "local": [ "alrn-20230216_pre.xml" ] }, "schema": { "local": [ "alrn-20230216.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alrn", "nsuri": "http://www.aileronrx.com/20230216", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d433980d8k.htm", "contextRef": "duration_2023-02-16_to_2023-02-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d433980d8k.htm", "contextRef": "duration_2023-02-16_to_2023-02-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aileronrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001193125-23-046516-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-046516-xbrl.zip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